Author

H. Khamaisi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

J. Gopas· 2 shared J. Mahajna· 2 shared A. Agbarya· 1 shared R. Adawi· 1 shared R. Farah· 1 shared R. Korobochka· 1 shared Y. K. Carmi· 1 shared Y. Koren Carmi· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

9 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Gopas

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 24, 2023

Ascites in malignant ovarian cancer confer ovarian cancer cells chemoresistance to platinum. Combination treatment with crizotinib and 2-hydroxyestradiol restores platinum sensitivity.

Y. K. Carmi, A. Agbarya, H. Khamaisi…·J. Mahajna

DOI 10.1101/2023.09.24.559160

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintFeb 24, 2023

Secreted soluble factors from tumor-activated mesenchymal stromal cells confer platinum chemoresistance to ovarian cancer cells

Y. Koren Carmi, R. Adawi, H. Khamaisi…·J. Mahajna

This study identifies soluble factors from tumor-activated stromal cells that confer platinum chemoresistance to ovarian cancer cells and explores potential therapeutic strategies to restore sensitivity.

DOI 10.1101/2023.02.24.529885

𝕏 PostBluesky